BioMed Nexus

Stay on the Cutting Edge of Biotech, MedTech, and Pharma.

100% free, unsubscribe anytime.

LATEST ISSUES

Lilly Bets $3.8B on Psychedelics as the China Deadline Lands

Lilly Bets $3.8B on Psychedelics as the China Deadline Lands

Merck cracked the first oral PCSK9. And we map how the China fight actually ends.

Biogen's Tau Drug Wowed the Science and Spooked the Market

Biogen's Tau Drug Wowed the Science and Spooked the Market

An unprecedented tau drop, a missed endpoint, an 8% slide. Plus Celcuity's first approval.

AstraZeneca Bet $600M on China Again, Days Before the Deadline

AstraZeneca Bet $600M on China Again, Days Before the Deadline

Its biggest China upfront yet, right before Friday. Plus injectable Leqembi gets cleared.

Washington Wants China's Trials Back. It Has Three Days to Make Its Case.

Washington Wants China's Trials Back. It Has Three Days to Make Its Case.

Operation TrialBlazer is the carrot. Friday's deadline is the stick. Both aimed at the same problem.

AstraZeneca's Heart Drug Failed, and the ATTR Debate Just Reopened

AstraZeneca's Heart Drug Failed, and the ATTR Debate Just Reopened

Wainua flunked Phase 3. Meanwhile the China deadline hits Friday and the deals keep landing.

AstraZeneca Signed Two China Deals This Week, Probe and All

AstraZeneca Signed Two China Deals This Week, Probe and All

Eight days to the July 17 deadline and the deals keep coming. Plus Krazati stumbles and GSK walks.